Priapismus
Published on September 6, 2026
Risk Factors
Sickle cell disease/hemoglobinopathy, intracavernosal injection (ICI) of vasoactive agents, hematologic malignancies, use of PDE5 inhibitors or recreational drugs, pelvic/perineal trauma (non-ischemic type), hypercoagulable states, vasculitis
Etiology
Ischemic: impaired venous outflow from corpora cavernosa causing blood stasis, hypoxia, and acidosis. Non-ischemic: unregulated arterial inflow following trauma creating an arterio-lacunar fistula
Presentation
Ischemic: painful, fully rigid erection lasting >4 hours without sexual stimulation. Non-ischemic: painless, partially tumescent (not fully rigid) erection, often with history of perineal/penile trauma
Classic Exam
Ischemic: rigid corpora cavernosa, glans and corpus spongiosum soft, tenderness on palpation. Non-ischemic: partial tumescence without full rigidity, no tenderness
Diagnostics
Ischemic: aspirated blood is dark; blood gas shows pO2 <30 mmHg, pCO2 >60 mmHg, pH <7.25; CDUS shows absent cavernosal arterial flow. Non-ischemic: aspirated blood is bright red; blood gas resembles arterial blood (pO2 >90, pCO2 <40, pH 7.40); CDUS shows turbulent flow at fistula site
Management
Ischemic (emergency): stepwise approach of aspiration, irrigation with normal saline, intracavernosal phenylephrine injection (200 mcg every 3-5 min, max 1 mg/hour); surgical shunting if refractory; penile prosthesis if >48 hours. Non-ischemic (not an emergency): observation, perineal compression; selective arterial embolization if conservative management fails
Keywords
"Painful erection >4 hours," "dark blood on aspiration," "sickle cell disease with erection," "perineal trauma with painless erection," "acidotic cavernosal blood gas," "absent arterial flow on Doppler"
01Pathophysiology
Priapism is defined as a persistent erection lasting more than 4 hours in the absence of sexual stimulation (Tata Laksana Disfungsi Seksual Pria IAUI 2023). The underlying mechanism differs fundamentally between the two principal subtypes, and understanding this distinction is what drives both diagnosis and management.
In ischemic (low-flow, veno-occlusive) priapism, the problem is a failure of venous drainage from the corpora cavernosa. Under normal physiology, detumescence occurs when sympathetic tone causes smooth muscle contraction, which reopens venous channels and allows blood to exit. When this mechanism fails, blood becomes trapped within the sinusoidal spaces. As time progresses, the trapped blood undergoes progressive deoxygenation, hypercapnia, and acidosis. This is why aspirated blood is characteristically dark, and the blood gas profile shows pO2 <30 mmHg, pCO2 >60 mmHg, and pH <7.25. If left untreated, the ischemic environment leads to smooth muscle necrosis and corporal fibrosis, which is irreversible and results in permanent erectile dysfunction. This makes ischemic priapism a true urological emergency. Ischemic priapism accounts for more than 95% of all cases (Tata Laksana Disfungsi Seksual Pria IAUI 2023).
In non-ischemic (high-flow, arteriogenic) priapism, the mechanism is entirely different. A traumatic event, most commonly blunt perineal or penile trauma, disrupts a cavernosal artery and creates an arterio-lacunar fistula. This fistula allows unregulated arterial inflow into the sinusoidal spaces, but because venous outflow remains intact, there is no ischemia. The blood within the corpora remains well-oxygenated. This is why the erection is typically only partial (not fully rigid), painless, and not a medical emergency. It accounts for only about 5% of all priapism cases (Tata Laksana Disfungsi Seksual Pria IAUI 2023).
Stuttering (recurrent/intermittent) priapism is a distinct entity characterized by repeated, self-limiting episodes of ischemic priapism that resolve spontaneously but recur over time. If untreated, cumulative episodes lead to progressive corporal fibrosis. Sickle cell disease is the most common underlying cause (Tata Laksana Disfungsi Seksual Pria IAUI 2023).
02Classification and Clinical Manifestation
Proportion of cases
Ischemic (Low-Flow)
>95%
Non-Ischemic (High-Flow)
~5%
Stuttering
Subset of ischemic
Mechanism
Ischemic (Low-Flow)
Impaired venous outflow
Non-Ischemic (High-Flow)
Unregulated arterial inflow via fistula
Stuttering
Recurrent episodes of venous outflow failure
Corpora cavernosa rigidity
Ischemic (Low-Flow)
Fully rigid (typical)
Non-Ischemic (High-Flow)
Rarely fully rigid
Stuttering
Fully rigid during episodes
Pain
Ischemic (Low-Flow)
Typical (severe)
Non-Ischemic (High-Flow)
Rare
Stuttering
Present during episodes
Onset
Ischemic (Low-Flow)
Spontaneous or drug-induced
Non-Ischemic (High-Flow)
Post-traumatic
Stuttering
Recurrent, self-limiting
Blood gas on aspiration
Ischemic (Low-Flow)
Abnormal (dark blood, pO2 <30, pCO2 >60, pH <7.25)
Non-Ischemic (High-Flow)
Normal/arterial (bright red, pO2 >90, pCO2 <40, pH 7.40)
Stuttering
Abnormal during acute episodes
CDUS findings
Ischemic (Low-Flow)
Absent cavernosal arterial flow
Non-Ischemic (High-Flow)
Normal arterial flow with turbulent flow at fistula site
Stuttering
Absent flow during episodes
Hematologic disorders
Ischemic (Low-Flow)
Sometimes
Non-Ischemic (High-Flow)
Rare
Stuttering
Common (sickle cell disease)
History of ICI
Ischemic (Low-Flow)
Sometimes
Non-Ischemic (High-Flow)
Sometimes
Stuttering
Less common
Perineal trauma
Ischemic (Low-Flow)
Rare
Non-Ischemic (High-Flow)
Typical
Stuttering
Rare
Urgency
Ischemic (Low-Flow)
Emergency
Non-Ischemic (High-Flow)
Not an emergency
Stuttering
Each acute episode is treated as emergency
Risk of erectile dysfunction
Ischemic (Low-Flow)
High (smooth muscle necrosis)
Non-Ischemic (High-Flow)
Low
Stuttering
Cumulative risk with repeated episodes
Feature | Ischemic (Low-Flow) | Non-Ischemic (High-Flow) | Stuttering |
|---|---|---|---|
Proportion of cases | >95% | ~5% | Subset of ischemic |
Mechanism | Impaired venous outflow | Unregulated arterial inflow via fistula | Recurrent episodes of venous outflow failure |
Corpora cavernosa rigidity | Fully rigid (typical) | Rarely fully rigid | Fully rigid during episodes |
Pain | Typical (severe) | Rare | Present during episodes |
Onset | Spontaneous or drug-induced | Post-traumatic | Recurrent, self-limiting |
Blood gas on aspiration | Abnormal (dark blood, pO2 <30, pCO2 >60, pH <7.25) | Normal/arterial (bright red, pO2 >90, pCO2 <40, pH 7.40) | Abnormal during acute episodes |
CDUS findings | Absent cavernosal arterial flow | Normal arterial flow with turbulent flow at fistula site | Absent flow during episodes |
Hematologic disorders | Sometimes | Rare | Common (sickle cell disease) |
History of ICI | Sometimes | Sometimes | Less common |
Perineal trauma | Rare | Typical | Rare |
Urgency | Emergency | Not an emergency | Each acute episode is treated as emergency |
Risk of erectile dysfunction | High (smooth muscle necrosis) | Low | Cumulative risk with repeated episodes |
03Diagnostic Workup
Comprehensive history
Purpose
Determine duration, pain severity, prior episodes, medications, substance use, sickle cell/hemoglobinopathy status
Key Findings
Strong recommendation (Tata Laksana Disfungsi Seksual Pria IAUI 2023)
Physical examination
Purpose
Assess genitalia, perineum, abdomen; determine rigidity and tenderness
Key Findings
Rigid, tender corpora = ischemic; partial tumescence, non-tender = non-ischemic
Corporal blood gas analysis
Purpose
Differentiate ischemic from non-ischemic
Key Findings
Best initial differentiating test. Ischemic: pO2 <30, pCO2 >60, pH <7.25. Non-ischemic: resembles arterial blood
Color duplex ultrasonography (CDUS) of penis and perineum
Purpose
Assess cavernosal blood flow; detect fistula
Key Findings
Ischemic: absent arterial flow. Non-ischemic: normal flow + turbulent flow at fistula
CBC with differential, platelet count, coagulation profile
Purpose
Evaluate for hematologic disorders
Key Findings
Screen for sickle cell, leukemia, coagulopathy
Hemoglobinopathy screening
Purpose
Identify sickle cell disease or thalassemia in at-risk patients
Key Findings
Strong recommendation for ischemic priapism in at-risk populations
Penile MRI
Purpose
Assess smooth muscle viability in prolonged or refractory ischemic priapism
Key Findings
Weak recommendation; helps predict whether smooth muscle is viable or necrotic
Pudendal arteriography
Purpose
Pre-procedural mapping before embolization
Key Findings
Performed only when embolization is planned for non-ischemic priapism
Test | Purpose | Key Findings |
|---|---|---|
Comprehensive history | Determine duration, pain severity, prior episodes, medications, substance use, sickle cell/hemoglobinopathy status | Strong recommendation (Tata Laksana Disfungsi Seksual Pria IAUI 2023) |
Physical examination | Assess genitalia, perineum, abdomen; determine rigidity and tenderness | Rigid, tender corpora = ischemic; partial tumescence, non-tender = non-ischemic |
Corporal blood gas analysis | Differentiate ischemic from non-ischemic | Best initial differentiating test. Ischemic: pO2 <30, pCO2 >60, pH <7.25. Non-ischemic: resembles arterial blood |
Color duplex ultrasonography (CDUS) of penis and perineum | Assess cavernosal blood flow; detect fistula | Ischemic: absent arterial flow. Non-ischemic: normal flow + turbulent flow at fistula |
CBC with differential, platelet count, coagulation profile | Evaluate for hematologic disorders | Screen for sickle cell, leukemia, coagulopathy |
Hemoglobinopathy screening | Identify sickle cell disease or thalassemia in at-risk patients | Strong recommendation for ischemic priapism in at-risk populations |
Penile MRI | Assess smooth muscle viability in prolonged or refractory ischemic priapism | Weak recommendation; helps predict whether smooth muscle is viable or necrotic |
Pudendal arteriography | Pre-procedural mapping before embolization | Performed only when embolization is planned for non-ischemic priapism |
The first step in evaluating any priapism is a thorough history (strong recommendation, Tata Laksana Disfungsi Seksual Pria IAUI 2023). The history must include the duration of erection, the presence and severity of pain, any prior episodes and their treatment, current erectile function, use of vasoactive medications or recreational drugs, and a review for sickle cell disease, hemoglobinopathy, hypercoagulable states, vasculitis, and history of pelvic/perineal trauma.
Physical examination of the genitalia, perineum, and abdomen is the next step (strong recommendation). In ischemic priapism, the corpora cavernosa are fully rigid and tender, while the glans penis and corpus spongiosum remain soft. In non-ischemic priapism, the penis is only partially tumescent and typically non-tender.
The critical differentiating test is corporal blood gas analysis from aspirated blood (strong recommendation). This is the best initial test to distinguish ischemic from non-ischemic priapism. The reference blood gas values from the IAUI 2023 guideline are:
Normal arterial blood (same as non-ischemic priapism)
pO2 (mmHg)
>90
pCO2 (mmHg)
<40
pH
7.40
Normal mixed venous blood
pO2 (mmHg)
40
pCO2 (mmHg)
50
pH
7.35
Ischemic priapism (first aspiration)
pO2 (mmHg)
<30
pCO2 (mmHg)
>60
pH
<7.25
Source | pO2 (mmHg) | pCO2 (mmHg) | pH |
|---|---|---|---|
Normal arterial blood (same as non-ischemic priapism) | >90 | <40 | 7.40 |
Normal mixed venous blood | 40 | 50 | 7.35 |
Ischemic priapism (first aspiration) | <30 | >60 | <7.25 |
Color duplex ultrasonography (CDUS) of the penis and perineum should be performed before aspiration to differentiate ischemic from non-ischemic priapism (strong recommendation, Tata Laksana Disfungsi Seksual Pria IAUI 2023). In ischemic priapism, there is absent cavernosal arterial flow. In non-ischemic priapism, arterial flow is preserved and turbulent flow can be identified at the fistula site.
Laboratory workup (strong recommendation) includes CBC with differential, platelet count, and coagulation profile. In children, a comprehensive evaluation of all possible causes is required. Hemoglobinopathy screening is strongly recommended in patients with ischemic priapism who are at risk for sickle cell disease or thalassemia.
MRI of the penis is a weak recommendation, reserved for prolonged or refractory ischemic priapism as an adjunct to predict smooth muscle viability. This is useful when deciding between shunting procedures and immediate prosthesis implantation.
Pudendal arteriography is only indicated when arterial embolization is planned for non-ischemic priapism (strong recommendation).
04Management & Treatment
Ischemic Priapism (Emergency)
1
Intervention
Penile aspiration
Details
Local anesthesia; insert 16-18G wing needle through glans into corpora cavernosa or via lateral approach bilaterally; aspirate until bright red (arterial) blood is obtained
Recommendation Strength
Strong
2
Intervention
Corporal irrigation
Details
Irrigate with 0.9% normal saline
Recommendation Strength
Strong
3
Intervention
Intracavernosal sympathomimetic injection
Details
Phenylephrine 200 mcg every 3-5 minutes until detumescence (maximum dose: 1 mg in 1 hour)
Recommendation Strength
Strong
4 (if steps 1-3 fail)
Intervention
Repeat aspiration + sympathomimetic before surgery
Details
Repeat the above steps before considering surgical intervention
Recommendation Strength
Strong
5a (<24 hours)
Intervention
Distal shunt +/- tunneling (T-shunt)
Details
First-line surgical option
Recommendation Strength
Weak
5b (24-48 hours, no necrosis)
Intervention
Distal shunt; if failed, consider peno-scrotal decompression
Details
MRI penis to assess necrosis
Recommendation Strength
Weak
5b (24-48 hours, necrosis present)
Intervention
Penile prosthesis implantation
Details
Consider early implantation
Recommendation Strength
Weak
5c (>48 hours)
Intervention
Penile prosthesis implantation
Details
Prosthesis may be preferred over proximal shunting in delayed presentation
Recommendation Strength
Weak
Step | Intervention | Details | Recommendation Strength |
|---|---|---|---|
1 | Penile aspiration | Local anesthesia; insert 16-18G wing needle through glans into corpora cavernosa or via lateral approach bilaterally; aspirate until bright red (arterial) blood is obtained | Strong |
2 | Corporal irrigation | Irrigate with 0.9% normal saline | Strong |
3 | Intracavernosal sympathomimetic injection | Phenylephrine 200 mcg every 3-5 minutes until detumescence (maximum dose: 1 mg in 1 hour) | Strong |
4 (if steps 1-3 fail) | Repeat aspiration + sympathomimetic before surgery | Repeat the above steps before considering surgical intervention | Strong |
5a (<24 hours) | Distal shunt +/- tunneling (T-shunt) | First-line surgical option | Weak |
5b (24-48 hours, no necrosis) | Distal shunt; if failed, consider peno-scrotal decompression | MRI penis to assess necrosis | Weak |
5b (24-48 hours, necrosis present) | Penile prosthesis implantation | Consider early implantation | Weak |
5c (>48 hours) | Penile prosthesis implantation | Prosthesis may be preferred over proximal shunting in delayed presentation | Weak |
Non-Ischemic Priapism
1
Intervention
Observation + perineal compression
Details
Conservative first-line; consider androgen deprivation therapy (ADT) in adults only
Recommendation Strength
Weak
2 (if conservative fails)
Intervention
Selective arterial embolization
Details
Use temporary embolization materials first
Recommendation Strength
Strong (for embolization); Weak (for temporary materials)
3 (if recurrence after embolization)
Intervention
Repeat embolization with temporary or permanent agents
Details
For recurrent non-ischemic priapism
Recommendation Strength
Weak
4 (last resort)
Intervention
Surgical ligation of fistula
Details
Only when repeated embolization has failed
Recommendation Strength
Weak
Step | Intervention | Details | Recommendation Strength |
|---|---|---|---|
1 | Observation + perineal compression | Conservative first-line; consider androgen deprivation therapy (ADT) in adults only | Weak |
2 (if conservative fails) | Selective arterial embolization | Use temporary embolization materials first | Strong (for embolization); Weak (for temporary materials) |
3 (if recurrence after embolization) | Repeat embolization with temporary or permanent agents | For recurrent non-ischemic priapism | Weak |
4 (last resort) | Surgical ligation of fistula | Only when repeated embolization has failed | Weak |
Stuttering Priapism
Acute episode
Intervention
Manage as ischemic priapism
Details
Same stepwise approach
Recommendation Strength
Strong
Prevention
Intervention
Hormonal therapy (GnRH agonist/antagonist, antiandrogens)
Details
Do NOT use before sexual maturity is reached
Recommendation Strength
Weak
Prevention
Intervention
PDE5 inhibitor
Details
Start only when penis is in flaccid state
Recommendation Strength
Weak
Refractory cases
Intervention
Digoxin, alpha-adrenergic agonists, baclofen, gabapentin, or terbutaline
Details
Only for frequent, uncontrolled recurrence
Recommendation Strength
Weak
Phase | Intervention | Details | Recommendation Strength |
|---|---|---|---|
Acute episode | Manage as ischemic priapism | Same stepwise approach | Strong |
Prevention | Hormonal therapy (GnRH agonist/antagonist, antiandrogens) | Do NOT use before sexual maturity is reached | Weak |
Prevention | PDE5 inhibitor | Start only when penis is in flaccid state | Weak |
Refractory cases | Digoxin, alpha-adrenergic agonists, baclofen, gabapentin, or terbutaline | Only for frequent, uncontrolled recurrence | Weak |
Ischemic priapism is a urological emergency and must be treated as soon as possible, ideally within 4 to 6 hours (strong recommendation, Tata Laksana Disfungsi Seksual Pria IAUI 2023). The management follows a stepwise approach, and the clinician should advance to the next step only when the current one fails.
Step 1: Aspiration and irrigation. After administering local anesthesia to the penis, a 16-18G wing needle is inserted through the glans into the corpora cavernosa (or through the lateral aspect bilaterally). Dark, deoxygenated blood is aspirated until bright red arterial blood is obtained. The corpora are then irrigated with 0.9% normal saline.
Step 2: Intracavernosal sympathomimetic injection. If aspiration alone does not achieve detumescence, phenylephrine is injected intracavernosally at a dose of 200 mcg every 3 to 5 minutes until detumescence occurs. The maximum dose is 1 mg within 1 hour (Tata Laksana Disfungsi Seksual Pria IAUI 2023). Phenylephrine can cause hypertension and should be used with caution in patients with cardiovascular disease. Heart rate and blood pressure monitoring is recommended during and for 1 hour after injection. Phenylephrine is contraindicated in patients with a history of cerebrovascular disease and significant hypertension. In pediatric patients, the dose must be reduced.
For priapism secondary to ICI with vasoactive agents, the aspirated blood should be replaced with an intracavernosal sympathomimetic injection as the first step (strong recommendation).
Step 3: If still refractory, repeat the aspiration and sympathomimetic injection before considering surgery (strong recommendation).
Step 4: Surgical intervention. When aspiration and injection fail, the approach depends on the duration of priapism. For priapism lasting less than 24 hours, a distal shunt (such as a T-shunt) with or without tunneling is performed first. For 24 to 48 hours, MRI of the penis can help assess whether smooth muscle necrosis has occurred. If no necrosis is present, a distal shunt is attempted; if necrosis is confirmed, penile prosthesis implantation should be considered. For priapism lasting more than 48 hours, prosthesis implantation is generally preferred over proximal shunting (Tata Laksana Disfungsi Seksual Pria IAUI 2023).
If a proximal shunt has been performed previously and failed, or if the patient does not wish to proceed with immediate prosthesis, proximal shunting remains an option for cases under 48 hours (weak recommendation).
Important post-surgical consideration: If a shunt has already been performed, prosthesis implantation should be delayed to minimize the risk of infection and implant erosion (strong recommendation). The type of implant depends on the clinical situation, surgeon experience, availability, and cost. If a malleable prosthesis is placed initially, it can later be replaced with an inflatable prosthesis (strong recommendation).
Perioperative anticoagulation may reduce the recurrence of priapism (weak recommendation).
For sickle cell-related priapism, the penile management is identical to idiopathic ischemic priapism. Supportive measures include intravenous hydration, supplemental oxygen with bicarbonate alkalinization, and exchange transfusion, but these should not delay the initial treatment of the penis (strong recommendation, Tata Laksana Disfungsi Seksual Pria IAUI 2023).
Non-ischemic priapism is not an emergency. The first-line approach is conservative management with perineal compression at the site of the fistula. Androgen deprivation therapy may be considered in adults only (weak recommendation). If conservative management fails, selective arterial embolization is performed, initially using temporary embolization materials (strong and weak recommendations, respectively). If priapism recurs after embolization, the procedure can be repeated using temporary or permanent agents. Surgical ligation of the fistula is a last-resort option when repeated embolization fails (weak recommendation).
05Differential Diagnosis & Distractors
Non-ischemic priapism (when the vignette is ischemic)
Why It Looks Similar
Both present with prolonged erection >4 hours
Key Discriminator
Ischemic: painful, fully rigid, dark blood on aspiration, acidotic blood gas, absent arterial flow on CDUS. Non-ischemic: painless, partially rigid, bright red blood, normal blood gas, history of trauma
Ischemic priapism (when the vignette is non-ischemic)
Why It Looks Similar
Both involve prolonged erection
Key Discriminator
Non-ischemic: painless, history of perineal trauma, arterial blood gas values, turbulent flow at fistula on CDUS
Nocturnal penile tumescence (sleep-related erection)
Why It Looks Similar
Patient wakes up with erection
Key Discriminator
Normal sleep erections resolve spontaneously within minutes, are not painful, and do not last >4 hours
Pharmacologically induced erection (normal response to ICI or PDE5i)
Why It Looks Similar
Erection occurs after drug use
Key Discriminator
Normal pharmacologic erection resolves within 1-2 hours; priapism is diagnosed when erection persists beyond 4 hours despite no ongoing stimulation
Sickle cell vaso-occlusive crisis (without priapism)
Why It Looks Similar
Patient with sickle cell disease, pain
Key Discriminator
Vaso-occlusive crisis causes pain in bones and abdomen, not an isolated rigid painful erection. Priapism in sickle cell is a localized veno-occlusive event in the penis
Stuttering priapism (vs. single episode ischemic)
Why It Looks Similar
Both involve painful rigid erection
Key Discriminator
Stuttering priapism is characterized by recurrent, self-limiting episodes that resolve and recur; treatment includes prevention of future episodes with hormonal therapy or PDE5i (started when flaccid)
Peyronie's disease with erection difficulty
Why It Looks Similar
Both can present with abnormal erection and pain
Key Discriminator
Peyronie's involves a palpable plaque, curvature, and pain during erection that resolves with time; the erection itself is not prolonged beyond 4 hours
Differential | Why It Looks Similar | Key Discriminator |
|---|---|---|
Non-ischemic priapism (when the vignette is ischemic) | Both present with prolonged erection >4 hours | Ischemic: painful, fully rigid, dark blood on aspiration, acidotic blood gas, absent arterial flow on CDUS. Non-ischemic: painless, partially rigid, bright red blood, normal blood gas, history of trauma |
Ischemic priapism (when the vignette is non-ischemic) | Both involve prolonged erection | Non-ischemic: painless, history of perineal trauma, arterial blood gas values, turbulent flow at fistula on CDUS |
Nocturnal penile tumescence (sleep-related erection) | Patient wakes up with erection | Normal sleep erections resolve spontaneously within minutes, are not painful, and do not last >4 hours |
Pharmacologically induced erection (normal response to ICI or PDE5i) | Erection occurs after drug use | Normal pharmacologic erection resolves within 1-2 hours; priapism is diagnosed when erection persists beyond 4 hours despite no ongoing stimulation |
Sickle cell vaso-occlusive crisis (without priapism) | Patient with sickle cell disease, pain | Vaso-occlusive crisis causes pain in bones and abdomen, not an isolated rigid painful erection. Priapism in sickle cell is a localized veno-occlusive event in the penis |
Stuttering priapism (vs. single episode ischemic) | Both involve painful rigid erection | Stuttering priapism is characterized by recurrent, self-limiting episodes that resolve and recur; treatment includes prevention of future episodes with hormonal therapy or PDE5i (started when flaccid) |
Peyronie's disease with erection difficulty | Both can present with abnormal erection and pain | Peyronie's involves a palpable plaque, curvature, and pain during erection that resolves with time; the erection itself is not prolonged beyond 4 hours |
06Traps and High-Yield Pearls
The most common way students get priapism questions wrong is by confusing ischemic and non-ischemic subtypes and consequently choosing the wrong management. The vignette will often contain one or two distinguishing features that must be identified quickly. Pain and full rigidity point to ischemic. A history of perineal trauma with a painless, partially tumescent erection points to non-ischemic. Blood gas analysis is the confirmatory differentiator, and the cutoff values (pO2 <30, pCO2 >60, pH <7.25 for ischemic) must be memorized.
A second common trap is failing to recognize that ischemic priapism is an emergency while non-ischemic is not. Students may rush to embolization in non-ischemic cases (which is premature; conservative management is tried first) or delay intervention in ischemic cases (which causes irreversible damage). The management of ischemic priapism is strictly stepwise: aspiration first, then irrigation, then phenylephrine injection, then repeat before surgery. Skipping steps or going directly to surgery is incorrect unless prior steps have explicitly failed.
A third trap involves sickle cell disease. The question may present a child or young adult with sickle cell disease and priapism, and the student may be tempted to prioritize hematologic management (hydration, exchange transfusion, oxygen). While these supportive measures are important, the IAUI 2023 guideline emphasizes that penile management must not be delayed for systemic treatment. The penile protocol is identical to idiopathic ischemic priapism.
The phenylephrine dosing detail is another testable point: 200 mcg every 3-5 minutes with a ceiling of 1 mg in 1 hour, contraindicated in cerebrovascular disease and significant hypertension. Students who confuse this with epinephrine or adrenaline may select a wrong answer.
Finally, the decision tree for surgery hinges on duration. Under 24 hours: distal shunt. Between 24 and 48 hours: check for necrosis with MRI. Over 48 hours: prosthesis implantation is generally favored. If a shunt has already been performed, prosthesis implantation should be delayed to reduce infection risk. The core competency being tested is the ability to match the correct intervention to the duration and refractoriness of the priapism, while applying the stepwise management principle accurately.